Samsung Biologics Co.,Ltd.
207940
Rank in Stocks
#496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Share Price
$1,028.49
Market Cap
$47.88B
Change (1 day)
-3.67%
Change (1 year)
-18.37%
Country
KR
Trade Samsung Biologics Co.,Ltd. (207940)
Category
Healthcare
P/E ratio for Samsung Biologics Co.,Ltd. (207940)
P/E ratio as of October 2026 TTM: 35.01
According to Samsung Biologics Co.,Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.01. At the end of 2024 the company had a P/E ratio of 62.35.
P/E ratio history for Samsung Biologics Co.,Ltd. from 2014 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 35.01 | -20.30% |
| 2025 | 43.93 | -29.55% |
| 2024 | 62.35 | -4.77% |
| 2023 | 65.47 | -9.41% |
| 2022 | 72.28 | -52.89% |
| 2021 | 153.41 | -33.07% |
| 2020 | 229.20 | 60.62% |
| 2019 | 142.70 | 27.87% |
| 2018 | 111.59 | -141.55% |
| 2017 | -268.58 | 428.98% |
| 2016 | -50.77 | -1,002.80% |
| 2015 | 5.62 | -104.99% |
| 2014 | -112.60 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 30.83 | -11.94% |
US
|
|
| -29.16 | -183.29% |
US
|
|
| -25.99 | -174.24% |
AU
|
|
| 22.43 | -35.93% |
BE
|
|
| 31.22 | -10.84% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.